Activation of inflammation and coagulation after infusion of C-reactive protein in humans

Circ Res. 2005 Apr 15;96(7):714-6. doi: 10.1161/01.RES.0000163015.67711.AB. Epub 2005 Mar 17.

Abstract

C-reactive protein (CRP) has been postulated to play a causal part in atherosclerosis and its acute complications. We assessed the effects of CRP-infusion on coagulation and inflammatory pathways to determine its role in atherothrombotic disease. Seven male volunteers received an infusion on two occasions, containing 1.25 mg/kg recombinant human CRP (rhCRP) or diluent, respectively. CRP-concentrations rose after rhCRP-infusion from 1.9 (0.3 to 8.5) to 23.9 (20.5 to 28.1) mg/L, and subsequently both inflammation and coagulation were activated. This sequence of events suggests that CRP is not only a well known marker of cardiovascular disease, but is also probably a mediator of atherothrombotic disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Arteriosclerosis / etiology*
  • Blood Coagulation / drug effects*
  • C-Reactive Protein / analysis
  • C-Reactive Protein / toxicity*
  • Fibrin Fibrinogen Degradation Products / analysis
  • Humans
  • Inflammation / chemically induced*
  • Interleukin-6 / blood
  • Lipopolysaccharides / toxicity
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / blood
  • Recombinant Proteins / toxicity

Substances

  • Fibrin Fibrinogen Degradation Products
  • Interleukin-6
  • Lipopolysaccharides
  • Plasminogen Activator Inhibitor 1
  • Recombinant Proteins
  • fibrin fragment D
  • C-Reactive Protein